1[2]Lieberman J.American psychiatric publishing textbook of psychopharmacology[M].Third Edition.American Psychiatric Publishing,2004:487-493.
2[3]Potkin SG,saha AR,Kujawa MJ,et al Aripipra zole,an antipsychotic with a novel mechanism of action,and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder[J].Arch Gen Psychiatry,2003,60(7):681-690.
7Jeffrey A lieberman.Dopamin partial agonists:a new class of antipsychotic[J].CNS Drags,2004,18:251-267.
8Lenox RH,McNaamara RK,Watterson JM,et al.Myristoy lated alaninerich C Kinase substrate(MARCKS):a molecular target for the therapeutic action of mood stabilizers in the brain? [J]J Clin Psychiatry,1996,57(Suppl 13):23-31.
9Fleishehacker WWW. New. devolepents in the pharmacotherapy of schizophrenia. J Neural transm Suppl, 2003,105~117
10Mader SR, McQuade RD, Stock E, et al. Aripiprazole in the treatment of schizophrenia: safe ana tolerability in shortterm, placebo-controlled trials, Schizophr Res, 2003, (61) : 123-136
7Anthony D,Patel N,Lynn C.Aripiprazole:a comprehensive review of its pharmacology,clinic efficacy and tolerability[J].Chinical Therapeutics,2004,26(5):649-666.
